ASU, Pfizer Partner on $5M Type 2 Diabetes Biomarker Project | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Arizona State University's Biodesign Institute will lead a study with partners at Pfizer, the Phoenix VA Healthcare System, and the University of Arizona's BIO5 Institute aimed at discovering protein biomarkers to predict cardiovascular disease in people with type 2 diabetes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: carbapenem resistance in Enterobacteriaceae, selection against educational attainment-linked variants, and more.

Technology Review points out that a new US presidential science advisor hasn't been selected.

Researchers find that blood tests might be able to help determine severity of a concussion, Wired reports.

President-elect Donald Trump considers other candidates for director of the National Institutes of Health, Nature News reports.